← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › Other monoclonal antibodies and antibody drug conjugates
patritumab deruxtecan
L01FX36
Forms & Strengths
- Lyophilized powder for injection: 100 mg per single-dose vial
Adult Dosing
- 5.6 mg/kg intravenously once every 3 weeks until disease progression or unacceptable toxicity
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have received prior systemic therapy
Mechanism of Action
- Antibody-drug conjugate (ADC) directed against HER3 (ErbB3), composed of a humanized anti-HER3 IgG1 monoclonal antibody linked to a topoisomerase I inhibitor payload (DXd) via a tetrapeptide-based cleavable linker
Contraindications
- Severe hypersensitivity to patritumab deruxtecan or any of its excipients
Adverse Reactions
- Interstitial lung disease (ILD) / pneumonitis
- Nausea
- Fatigue
- Decreased lymphocyte count
- Decreased neutrophil count
- Vomiting
- Alopecia
- Constipation
- Decreased hemoglobin
- Decreased platelet count
Drug Interactions
- Strong CYP3A inhibitors may increase exposure to the DXd payload
- Strong CYP3A inducers may decrease exposure to the DXd payload
- Concomitant use with other agents known to cause interstitial lung disease may increase the risk of severe pneumonitis
Curated Content: Needs Vetting Before Put to Clinical Use